Journal article

A sporadic Alzheimer’s blood-brain barrier model for developing ultrasound-mediated delivery of Aducanumab and anti-Tau antibodies

JM Wasielewska, JCS Chaves, RL Johnston, LA Milton, D Hernández, L Chen, J Song, W Lee, G Leinenga, RM Nisbet, A Pébay, J Götz, AR White, LE Oikari

Theranostics | Published : 2022

Abstract

Rationale: The blood-brain barrier (BBB) is a major impediment to therapeutic intracranial drug delivery for the treatment of neurodegenerative diseases, including Alzheimer’s disease (AD). Focused ultrasound applied together with microbubbles (FUS+MB) is a novel technique to transiently open the BBB and increase drug delivery. Evidence suggests that FUS+MB is safe, however, the effects of FUS+MB on human BBB cells, especially in the context of AD, remain sparsely investigated. In addition, there currently are no cell platforms to test for FUS+MB-mediated drug delivery. Methods: Here we generated BBB cells (induced brain endothelial-like cells (iBECs) and astrocytes (iAstrocytes)) from apoli..

View full abstract

University of Melbourne Researchers

Grants

Awarded by National Health and Medical Research Council


Funding Acknowledgements

This work was supported by: National Health and Medical Research Council (NHMRC) Senior Research Fellowship (1154389) (AP); National Health and Medical Research Council (NHMRC) Senior Research Fellowship (1118452) (ARW). DH was supported by Yulgilbar Alzheimer's Research Program grant. JMW is a recipient of The University of Queensland PhD scholarship.